PARP AND ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN NON-SMALL-CELL LUNG CANCER
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Nov 1, 2012
app pub date -
Jul 26, 2010
filing date -
Jul 24, 2009
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
The invention is generally directed to a diagnostic method for predicting the benefit of the response of a subject diagnosed with cancer to a platinum compound-based adjuvant chemotherapy, preferably to a cisplatin-based chemotherapy which implements the determination of the PARP expression level in the biological sample containing tumor cells, and, preferably, together with the MSH2 and/or ERCC1 expression level, more preferably together with the MSH2 and ERCC1 expression levels.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully